Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Incyte

< Previous 1 2 3 4 5 Next >
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
From Incyte
Via Business Wire
Tickers INCY
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
From Incyte
Via Business Wire
Tickers INCY
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
From Incyte
Via Business Wire
Tickers INCY
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte Completes Acquisition of Escient Pharmaceuticals
From Incyte
Via Business Wire
Tickers INCY
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
From Incyte
Via Business Wire
Tickers INCY
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.